The other genes, CDH2, SNAI1, and ZEB1, showed no significant difference between tumor and healthy control, while the expression of ZEB2 is downregulated in breast, lung, and ovarian cancer patients compared to healthy controls, with no significant change observed in prostate cancer. This evidence concerns the gene ZEB2 and prostate cancer.